Streetbeat News

Price Targets

DOTUSD

Polkadot's (CRYPTO: DOT) price has risen by 3.14% in the last 24 hours, reaching $8.65, with a 7% increase over the past week from $8.07. Despite a 55% drop in trading volume over the week, the circulating supply has grown by 0.23% to 1.31 billion. Polkadot's market cap is currently ranked #12 at $11.32 billion.

Portfolio Pulse from Benzinga Insights

December 29, 2023 | 3:02 pm

ACRS

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Aclaris Therapeutics (NASDAQ:ACRS) and maintained a price target of $9.

Portfolio Pulse from Benzinga Newsdesk

December 29, 2023 | 2:25 pm

CCL

Macquarie analyst Paul Golding has maintained an Outperform rating on Carnival Corporation (NYSE:CCL) and increased the price target from $16 to $22.

Portfolio Pulse from Benzinga Newsdesk

December 29, 2023 | 2:24 pm

VTSI

Lake Street analyst Jaeson Schmidt has reaffirmed a Buy rating on VirTra (NASDAQ:VTSI) and increased the price target from $9 to $13, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 29, 2023 | 2:21 pm

ACAD

ATUS

BKNG

COP

EFX

EXPE

NEO

NTRA

OTLK

UBER

Several top Wall Street analysts have updated their price targets and ratings for various companies. Notable changes include Nomura's downgrade of Uber from Buy to Neutral with a price target increase, Goldman Sachs' price target raise for Equifax while maintaining a Neutral rating, and Ascendiant Capital's price target increases for Expedia, Booking Holdings, and Outlook Therapeutics with maintained Buy ratings. Other firms like BTIG, Raymond James, TD Cowen, Benchmark, and Mizuho also adjusted their price targets for Natera, ConocoPhillips, NeoGenomics, Altice USA, and ACADIA Pharmaceuticals, respectively.

Portfolio Pulse from Avi Kapoor

December 29, 2023 | 2:20 pm

PFE

SNY

TAK

Pfizer, Sanofi, and Takeda are set to increase prices on over 500 unique drugs in the US in early January, according to data from 3 Axis Advisors reported by Reuters.

Portfolio Pulse from Charles Gross

December 29, 2023 | 2:17 pm

NEO

TD Cowen analyst Dan Brennan has maintained an Outperform rating on NeoGenomics (NASDAQ:NEO) but has lowered the price target from $22 to $19.

Portfolio Pulse from Benzinga Newsdesk

December 29, 2023 | 1:40 pm

CGAU

Raymond James analyst Brian MacArthur has maintained an Outperform rating on Centerra Gold (NYSE:CGAU) but has reduced the price target from C$12 to C$11.

Portfolio Pulse from Benzinga Newsdesk

December 29, 2023 | 1:37 pm

ALNY

ARWR

IBB

LEGN

PIPR

SPY

Piper Sandler Cos has selected Arrowhead Pharmaceuticals, Legend Biotech, and Alnylam Pharmaceuticals as top biotech picks for 2024, predicting a sector comeback. Arrowhead's gene therapies, Legend's Carvykti for bone marrow cancer, and Alnylam's focus on neurological disorders are key highlights. Despite recent share price declines, Piper Sandler forecasts significant share price increases for these companies over the next 12 months. The biotech sector's performance, as tracked by the iShares Biotechnology ETF, has lagged behind the broader market, represented by the SPDR S&P 500 ETF.

Portfolio Pulse from Surbhi Jain

December 29, 2023 | 1:34 pm

VRNA

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Verona Pharma (NASDAQ:VRNA) and maintained a price target of $32.

Portfolio Pulse from Benzinga Newsdesk

December 29, 2023 | 1:28 pm